|
| | |
|
Am J Psychiatry 1990; 147:1493-1497
Copyright © 1990 by American Psychiatric Association
Antidepressant pharmacotherapy of depression associated with multiple sclerosis
RB Schiffer and NM Wineman
Department of Psychiatry, University of Rochester Medical Center.
In a double-blind clinical trial involving 28 patients with multiple
sclerosis and major depressive disorder, 14 patients were randomly assigned
to a 5-week trial of desipramine and individual psychotherapy and 14 to
placebo plus psychotherapy. Clinical judgments indicated that patients
treated with desipramine improved significantly more than the placebo
group. This was confirmed by scores on the Hamilton Rating Scale for
Depression but not by Beck Depression Inventory scores. Side effects
limited desipramine dosage in half of the treated patients. The authors
conclude that desipramine has a modest beneficial effect in serious
depression associated with multiple sclerosis but that side effects may be
more of a limiting factor than in patients without medical or neurologic
disease.
This article has been cited by other articles:
|
|
|
|
 
S. Patten, J. Williams, and L. Metz
Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis
Multiple Sclerosis,
April 1, 2008;
14(3):
406 - 411.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Cetin, K.L. Johnson, D.M. Ehde, C.M. Kuehn, D. Amtmann, and G.H. Kraft
Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample
Multiple Sclerosis,
September 1, 2007;
13(8):
1046 - 1053.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Jefferies
The neuropsychiatry of multiple sclerosis
Advan. Psychiatr. Treat.,
May 1, 2006;
12(3):
214 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D C Mohr, S L Hart, I Fonareva, and E S Tasch
Treatment of depression for patients with multiple sclerosis in neurology clinics
Multiple Sclerosis,
April 1, 2006;
12(2):
204 - 208.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Goldman Consensus Group
The Goldman Consensus statement on depression in multiple sclerosis
Multiple Sclerosis,
June 1, 2005;
11(3):
328 - 337.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R J Siegert and D A Abernethy
Depression in multiple sclerosis: a review
J. Neurol. Neurosurg. Psychiatry,
April 1, 2005;
76(4):
469 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Benedetti, E. Campori, C. Colombo, and E. Smeraldi
Fluvoxamine Treatment of Major Depression Associated With Multiple Sclerosis
J Neuropsychiatry Clin Neurosci,
August 1, 2004;
16(3):
364 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Krupp and S. A. Rizvi
Symptomatic therapy for underrecognized manifestations of multiple sclerosis
Neurology,
April 23, 2002;
58(90084):
S32 - 39.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. A. Posternak, M. Zimmerman, G. I. Keitner, and I. W. Miller
A Reevaluation of the Exclusion Criteria Used in Antidepressant Efficacy Trials
Am J Psychiatry,
February 1, 2002;
159(2):
191 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Feinstein
Multiple sclerosis, disease modifying treatments and depression: a critical methodological review
Multiple Sclerosis,
October 1, 2000;
6(5):
343 - 348.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. B Patten, L. M Metz, and M. A Reimer
Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population
Multiple Sclerosis,
April 1, 2000;
6(2):
115 - 120.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. C. Mohr, W. Likosky, P. Dwyer, J. Van Der Wende, A. C. Boudewyn, and D. E. Goodkin
Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
Arch Neurol,
October 1, 1999;
56(10):
1263 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1990
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
